Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 52
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Nucl Med Biol ; 72-73: 55-61, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31330413

RESUMO

INTRODUCTION: [N-methyl-11C]cholylsarcosine ([11C]CSar) is a tracer for imaging and quantitative assessment of intrahepatic cholestatic liver diseases and drug-induced cholestasis by positron emission tomography (PET). The purpose of this study is to determine whole-body biodistribution and dosimetry of [11C]CSar in healthy humans. The results are compared with findings in a patient with primary sclerosing cholangitis (PSC) and a patient with primary biliary cholangitis (PBC) as well as with preclinical findings in pigs. Radiosynthesis and quality control for preparation of [11C]CSar for clinical use are also presented. METHODS: Radiosynthesis and quality control of [11C]CSar were set up in compliance with Danish/European regulations. Both healthy participants (3 females, 3 males) and patients underwent whole-body PET/CT to determine the biodistribution of [11C]CSar. The two patients were under treatment with ursodeoxycholic acid at the time of the study. Dosimetry was estimated from the PET data using the Olinda 2.0 software. RESULTS: The radiosynthesis provided [11C]CSar in a solution ready for injection. The biodistribution studies revealed that gallbladder wall, small intestine, and liver were critical organs in both healthy participants and patients with the gallbladder wall receiving the highest dose (up to 0.5 mGy/MBq). The gender-averaged (±SD) effective dose for the healthy participants was 6.2 ±â€¯1.4 µSv/MBq. The effective dose for the PSC and the PBC patient was 5.2 and 7.0 µSv/MBq, respectively. CONCLUSION: A radiosynthesis for preparation of [11C]CSar for clinical use was developed and approved by the Danish Medicines Agency. The most critical organ was the gallbladder wall although the amount of [11C]CSar in the gallbladder was found to vary significantly between individuals. The estimated effective dose for humans was comparable to that estimated in anesthetized pigs although the absorbed dose estimates to some organs, such as the stomach, was different. ADVANCES IN KNOWLEDGE AND IMPLICATIONS FOR PATIENT CARE: [11C]CSar PET/CT enables detailed quantitative assessment of patients with cholestatic liver disease by tracing the separate hepatobiliary transport steps of endogenous bile acids. The present work offers a radiosynthetic method and dosimetry data suitable for clinical implementation of [11C]CSar.


Assuntos
Ácidos e Sais Biliares/farmacocinética , Colestase Intra-Hepática/metabolismo , Ácidos Cólicos/farmacocinética , Fígado/metabolismo , Traçadores Radioativos , Compostos Radiofarmacêuticos/farmacocinética , Sarcosina/análogos & derivados , Adulto , Idoso , Animais , Ácidos e Sais Biliares/química , Radioisótopos de Carbono , Estudos de Casos e Controles , Colestase Intra-Hepática/patologia , Ácidos Cólicos/química , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Tomografia por Emissão de Pósitrons , Compostos Radiofarmacêuticos/química , Sarcosina/química , Sarcosina/farmacocinética , Suínos , Distribuição Tecidual
2.
SAR QSAR Environ Res ; 28(6): 427-449, 2017 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-28573881

RESUMO

Finding a balance between a desired drug's potency and its physicochemical properties that are important for its molecule pharmacokinetic or pharmacodynamics profile is still a challenging issue in rational drug discovery. Quantitative assessment of the lipophilic characteristics of potential drug molecules is indispensable for efficient development of Absorption, Distribution, Metabolism, Excretion, Toxicity-tailored structure-activity models; therefore reliable procedures for deriving log P from molecular structure are desirable. In the current work a range of various software log P predictors for estimation of the numerical lipophilic values for a set of cholic acid derivatives were employed and subsequently cross-compared with the experimental parameters. Thus, the empirical lipophilicity (RM) was compared with the corresponding log P characteristics calculated using alternative methods for deducing the lipophilic features. The mean values of the selected molecular descriptors that were averaged over the chosen calculation methods (consensus clog P) were subsequently correlated with the RM parameter. As an additional experiment, the iterative variable elimination partial least squares (IVE-PLS) methodology for an ensemble of descriptors retrieved from Dragon 6.0 software was applied for a set of drug transporters. To investigate the variations within the ensemble of cholic acid derivatives principal component analysis (PCA) and self-organizing neural network (SOM) procedures were used to visualize the major differences in the performance of drug promoters with respect to their lipophilic profile.


Assuntos
Ácidos Cólicos/química , Ácidos Cólicos/farmacocinética , Preparações Farmacêuticas/química , Adsorção , Química Farmacêutica/métodos , Simulação por Computador , Descoberta de Drogas/métodos , Interações Hidrofóbicas e Hidrofílicas , Análise dos Mínimos Quadrados , Lipídeos/química , Estrutura Molecular , Redes Neurais de Computação , Análise de Componente Principal , Relação Quantitativa Estrutura-Atividade
3.
J Hepatol ; 67(2): 321-327, 2017 08.
Artigo em Inglês | MEDLINE | ID: mdl-28249726

RESUMO

BACKGROUND & AIMS: Hepatobiliary secretion of bile acids is an important liver function. Here, we quantified the hepatic transport kinetics of conjugated bile acids using the bile acid tracer [N-methyl-11C]cholylsarcosine (11C-CSar) and positron emission tomography (PET). METHODS: Nine healthy participants and eight patients with varying degrees of cholestasis were examined with 11C-CSar PET and measurement of arterial and hepatic venous blood concentrations of 11C-CSar. RESULTS: Results are presented as median (range). The hepatic intrinsic clearance was 1.50 (1.20-1.76) ml blood/min/ml liver tissue in healthy participants and 0.46 (0.13-0.91) in patients. In healthy participants, the rate constant for secretion of 11C-CSar from hepatocytes to bile was 0.36 (0.30-0.62)min-1, 20 times higher than the rate constant for backflux from hepatocytes to blood (0.02, 0.005-0.07min-1). In the patients, rate constant for transport from hepatocyte to bile was reduced to 0.12 (0.006-0.27)min-1, 2.3times higher than the rate constant for backflux to blood (0.05, 0.04-0.09). The increased backflux did not fully normalize exposure of the hepatocyte to bile acids as mean hepatocyte residence time of 11C-CSar was 2.5 (1.6-3.1)min in healthy participants and 6.4 (3.1-23.7)min in patients. The rate constant for transport of 11C-CSar from intrahepatic to extrahepatic bile was 0.057 (0.023-0.11)min-1 in healthy participants and only slightly reduced in patients 0.039 (0.017-0.066). CONCLUSIONS: This first in vivo quantification of individual steps involved in the hepatobiliary secretion of a conjugated bile acid in humans provided new insight into cholestatic disease. LAY SUMMARY: Positron emission tomography (PET) using the radiolabelled bile acid (11C-CSar) enabled quantification of the individual steps of the hepatic transport of bile acids from blood to bile in man. Cholestasis reduced uptake and secretion and increased backflux to blood. These findings improve our understanding of cholestatic liver diseases and may support therapeutic decisions. CLINICAL TRIAL REGISTRATION NUMBER: The trial is registered at ClinicalTrials.gov (NCT01879735).


Assuntos
Ácidos e Sais Biliares/metabolismo , Colestase/metabolismo , Ácidos Cólicos/farmacocinética , Sarcosina/análogos & derivados , Idoso , Bile/metabolismo , Transporte Biológico Ativo , Radioisótopos de Carbono , Estudos de Casos e Controles , Colestase/sangue , Colestase/diagnóstico por imagem , Ácidos Cólicos/sangue , Feminino , Humanos , Cinética , Fígado/diagnóstico por imagem , Fígado/metabolismo , Circulação Hepática , Masculino , Pessoa de Meia-Idade , Tomografia por Emissão de Pósitrons , Sarcosina/sangue , Sarcosina/farmacocinética , Adulto Jovem
4.
Biomaterials ; 75: 47-57, 2016 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-26480471

RESUMO

A novel MRI blood-pool contrast agent (Gd-AAZTA-MADEC) has been compared with established blood pool agents for tumor contrast enhanced images and angiography. Synthesis, relaxometric properties, albumin binding affinity and pharmacokinetic profiles are reported. For in vivo studies, angiographic images and tumor contrast enhanced images were acquired on mice with benchtop 1T-MRI scanners and compared with MS-325, B22956/1 and B25716/1. The design of this contrast agent involved the elongation of the spacer between the targeting deoxycholic acid moiety and the Gd-AAZTA imaging reporting unit that drastically changed either the binding affinity to albumin (KA(HSA) = 8.3 × 10(5) M(-1)) and the hydration state of the Gd ion (q = 2) in comparison to the recently reported B25716/1. The very markedly high binding affinity towards mouse and human serum albumins resulted in peculiar pharmacokinetics and relaxometric properties. The NMRD profiles clearly indicated that maximum efficiency is attainable at magnetic field strength of 1 T. In vivo studies showed high enhancement of the vasculature and a prolonged accumulation inside tumor. The herein reported pre-clinical imaging studies show that a great benefit arises from the combination of a benchtop MRI scanner operating at 1 T and the albumin-binding Gd-AAZTA-MADEC complex, for pursuing enhanced angiography and improved characterization of tumor vascular microenvironment.


Assuntos
Ácidos Cólicos/química , Meios de Contraste/química , Complexos de Coordenação/química , Imagem do Acúmulo Cardíaco de Comporta , Imageamento por Ressonância Magnética/instrumentação , Animais , Ácidos Cólicos/sangue , Ácidos Cólicos/síntese química , Ácidos Cólicos/farmacocinética , Complexos de Coordenação/sangue , Complexos de Coordenação/síntese química , Complexos de Coordenação/farmacocinética , Humanos , Angiografia por Ressonância Magnética , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Neoplasias/diagnóstico , Ligação Proteica , Espectroscopia de Prótons por Ressonância Magnética , Prótons , Albumina Sérica/metabolismo , Distribuição Tecidual , Água
5.
Int J Nanomedicine ; 8: 1921-33, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23690687

RESUMO

The objective of this study was to investigate the potential of liposomes containing bile salts as an ophthalmic delivery system for tacrolimus to improve corneal permeability. Liposomes containing bile salts, including sodium taurocholate, sodium deoxycholate, and sodium glycocholate, were produced by the thin-film dispersion method with a particle size of approximately 100 nm and an entrapment efficiency of more than 90%. Less than 5% tacrolimus was released from conventional liposomes and from liposomes containing sodium taurocholate, sodium deoxycholate, or sodium glycocholate over 12 hours. The cellular uptake of conventional liposomes was significantly higher than that of liposomes containing bile salts. However, liposomes containing bile salts exerted a 3-4-fold increase of tacrolimus in ex vivo corneal transport of tacrolimus compared with conventional liposomes. When rabbit eyes were treated with a DiI perchlorate-loaded liposome suspension, liposomes containing bile salts showed fast and sustained penetration across the cornea. Unfortunately, liposomes containing sodium deoxycholate caused toxicity or irritation to both spontaneously derived human corneal epithelial cells and the rabbit cornea. Therefore, liposomes containing sodium taurocholate and sodium glycocholate are potential carriers in ocular drug delivery systems, given their low toxicity and vastly improved permeability.


Assuntos
Ácidos Cólicos/farmacocinética , Portadores de Fármacos/farmacocinética , Lipossomos/farmacocinética , Tacrolimo/farmacocinética , Administração Oftálmica , Análise de Variância , Animais , Sobrevivência Celular/efeitos dos fármacos , Ácidos Cólicos/administração & dosagem , Ácidos Cólicos/química , Ácidos Cólicos/toxicidade , Córnea/efeitos dos fármacos , Córnea/patologia , Portadores de Fármacos/administração & dosagem , Portadores de Fármacos/química , Portadores de Fármacos/toxicidade , Lipossomos/administração & dosagem , Lipossomos/química , Lipossomos/toxicidade , Tamanho da Partícula , Coelhos , Tacrolimo/administração & dosagem , Tacrolimo/química
6.
J Nucl Med ; 53(5): 772-8, 2012 May.
Artigo em Inglês | MEDLINE | ID: mdl-22454486

RESUMO

UNLABELLED: Excretion of conjugated bile acids into bile is an essential function of the liver, and impairment of canalicular bile acid secretion leads to cholestatic liver injury. However, hepatic excretory function cannot be quantified in vivo because of the lack of suitable methods. Cholylsarcosine is an analog of the endogenous bile acid conjugate cholylglycine and exhibits characteristics in vivo that led us to hypothesize that the (11)C-labeled form, that is, [N-methyl-(11)C]cholylsarcosine ((11)C-cholylsarcosine), would be a suitable PET tracer for quantification of hepatic excretory function. METHODS: A method for radiosynthesis of (11)C-cholylsarcosine was developed involving (11)C-methylation of glycine followed by conjugation with cholic acid. Blood-to-liver uptake and liver-to-bile excretion were investigated in vivo by dynamic (11)C-cholylsarcosine PET/CT of 2 anesthetized pigs. In pig 1, a second dynamic (11)C-cholylsarcosine PET/CT examination was preceded by a high dose of the endogenous bile acid conjugate cholyltaurine to investigate possible inhibition of the transhepatocellular transport of (11)C-cholylsarcosine. In pig 2, a second (11)C-cholylsarcosine administration was given to determine the biodistribution of the tracer by means of 5 successive whole-body PET/CT recordings. Possible formation of (11)C-metabolites was investigated by analysis of blood and bile samples from a third pig. RESULTS: The radiochemical yield was 13% ± 3% (n = 7, decay-corrected) and up to 1.1 GBq of (11)C-cholylsarcosine was produced with a radiochemical purity greater than 99%. PET/CT studies showed rapid blood-to-liver uptake and liver-to-bile excretion of (11)C-cholylsarcosine, with radioactivity concentrations being more than 90 times higher in the bile ducts than in liver tissue. Cholyltaurine inhibited the transhepatocellular transport of (11)C-cholylsarcosine, indicating that the tracer is transported by one or more of the same hepatic transporters as cholyltaurine. (11)C-cholylsarcosine underwent an enterohepatic circulation and reappeared in liver tissue and bile ducts after approximately 70 min. There were no detectable (11)C-metabolites in the plasma or bile samples, indicating that the novel conjugated bile acid (11)C-cholylsarcosine was not metabolized in the liver or in the intestines. The effective absorbed dose of (11)C-cholylsarcosine was 4.4 µSv/MBq. CONCLUSION: We have synthesized a novel conjugated bile acid analog, (11)C-cholylsarcosine, and PET/CT studies on anesthetized pigs showed that the hepatic handling of tracer uptake from blood and excretion into the bile was comparable to that for the endogenous bile acid cholyltaurine. This tracer may be valuable for future studies of normal and pathologic hepatic excretory functions in humans.


Assuntos
Ácidos e Sais Biliares/metabolismo , Ácidos Cólicos/síntese química , Testes de Função Hepática/métodos , Fígado/diagnóstico por imagem , Fígado/fisiologia , Imagem Multimodal/métodos , Tomografia por Emissão de Pósitrons , Sarcosina/análogos & derivados , Tomografia Computadorizada por Raios X , Animais , Radioisótopos de Carbono , Ácidos Cólicos/metabolismo , Ácidos Cólicos/farmacocinética , Feminino , Fígado/metabolismo , Traçadores Radioativos , Radioquímica , Sarcosina/síntese química , Sarcosina/metabolismo , Sarcosina/farmacocinética , Suínos
7.
Eur J Drug Metab Pharmacokinet ; 37(2): 99-108, 2012 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-21874525

RESUMO

In recent studies we showed that gliclazide has no hypoglycemic effect on type 1 diabetic (T1D) rats while MKC does, and their combination exerted a better hypoglycemic effect than MKC alone. We also showed that the most hypoglycemic effect was noticed when T1D rats were treated with probiotics then gavaged with MKC + gliclazide (blood glucose decreased from 24 ± 3 to 10 ± 2 mmol/l). The aim of this study is to investigate the influence of probiotics on MKC pharmacokinetics when coadministered with gliclazide, in T1D rats. 80 male Wistar rats (weight 350 ± 50 g) were randomly allocated into 8 groups (10 rats/group), 4 of which were injected with alloxan (30 mg/kg) to induce T1D. Group 1 was healthy and group 2 was diabetic. Groups 3 (healthy) and 4 (diabetic) were gavaged with probiotics (75 mg/kg) every 12 h for 3 days and 12 h later all groups received a single oral dose of MKC + gliclazide (4 and 20 mg/kg respectively). The remaining 4 groups were treated in the same way but administered MKC + gliclazide via the i.v. route. Blood samples collected from T1D rats prior to MKC + gliclazide revealed that probiotic treatment alone reduced blood glucose levels twofold. When coadministered with gliclazide, the bioavailability of MKC was reduced in healthy rats treated with probiotics but remained the same in diabetic pretreated rats. The decrease in MKC bioavailability, when administered with gliclazide, caused by probiotic treatment in healthy but not diabetic rats suggests that probiotic treatment induced MKC metabolism or impaired its absorption, only in healthy animals. The different MKC bioavailability in healthy and diabetic rats could be explained by different induction of presystemic elimination of MKC in the gut by probiotic treatment.


Assuntos
Ácidos Cólicos/farmacocinética , Diabetes Mellitus Experimental/tratamento farmacológico , Gliclazida/farmacocinética , Hipoglicemiantes/farmacocinética , Probióticos/farmacologia , Administração Oral , Animais , Disponibilidade Biológica , Glicemia/efeitos dos fármacos , Ácido Quenodesoxicólico/análogos & derivados , Ácidos Cólicos/administração & dosagem , Cromatografia Líquida de Alta Pressão/métodos , Diabetes Mellitus Experimental/metabolismo , Diabetes Mellitus Tipo 1/tratamento farmacológico , Diabetes Mellitus Tipo 1/metabolismo , Quimioterapia Combinada , Interações Alimento-Droga , Gliclazida/administração & dosagem , Hipoglicemiantes/administração & dosagem , Injeções Intravenosas , Masculino , Distribuição Aleatória , Ratos , Ratos Wistar
8.
Curr Pharm Biotechnol ; 12(2): 285-92, 2011 Feb 01.
Artigo em Inglês | MEDLINE | ID: mdl-21190543

RESUMO

The liver X receptors (LXRs) are key regulators of genes involved in cholesterol homeostasis. Natural ligands and activators of LXRs are oxysterols. Numerous steroidal and non-steroidal synthetic LXR ligands are under development as potential drugs for individuals suffering from lipid disorders. N,N-dimethyl-3ß-hydroxycholenamide (DMHCA) is a steroidal ligand of LXRs that exerts anti-atherogenic effects in apolipoprotein E-deficient mice without causing negative side effects such as liver steatosis or hypertriglyceridemia. In this report, we investigated the consequences of DMHCA treatment on cholesterol homeostasis in vivo and in vitro. Despite its hydrophobicity, DMHCA is readily absorbed by C57BL/6 mice and taken up by intestinal cells, the lung, heart and kidneys, but is undetectable in the brain. DMHCA significantly reduces cholesterol absorption and uptake in duodenum and jejunum of the small intestine and in turn leads to a reduction of plasma cholesterol by 24%. The most striking finding of this study is that DMHCA inhibited the enzyme 3ß-hydroxysterol-Δ24-reductase resulting in an accumulation of desmosterol in the plasma and in feces. Thus, the reduction of plasma cholesterol was due to a block in the final step of cholesterol biosynthesis. Taken together, DMHCA is an interesting compound with properties distinct from other LXR ligands and might be used to study desmosterol-mediated effects in cells and tissues.


Assuntos
Anticolesterolemiantes/farmacologia , Colesterol/biossíntese , Ácidos Cólicos/farmacologia , Inibidores Enzimáticos/farmacologia , Metabolismo dos Lipídeos/efeitos dos fármacos , Lipogênese/efeitos dos fármacos , Receptores Nucleares Órfãos/agonistas , Androstenos/farmacocinética , Androstenos/farmacologia , Animais , Anticolesterolemiantes/farmacocinética , Anticolesterolemiantes/toxicidade , Sobrevivência Celular/efeitos dos fármacos , Colesterol/sangue , Colesterol/metabolismo , Ácidos Cólicos/farmacocinética , Desmosterol/metabolismo , Inibidores Enzimáticos/farmacocinética , Inibidores Enzimáticos/toxicidade , Fígado Gorduroso/induzido quimicamente , Fezes , Células Hep G2 , Humanos , Intestinos/efeitos dos fármacos , Receptores X do Fígado , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Proteínas do Tecido Nervoso/antagonistas & inibidores , Oxirredutases atuantes sobre Doadores de Grupo CH-CH/antagonistas & inibidores
9.
J Pharmacol Exp Ther ; 334(1): 78-86, 2010 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-20388726

RESUMO

Cholyl-L-lysyl-fluorescein (CLF) is a fluorescent bile salt derivative that is being developed as an agent for determining in vivo liver function. However, the mechanisms of uptake and excretion by hepatocytes have not been rigorously studied. We have directly assessed the transport capacity of various hepatobiliary transporters for CLF. Uptake experiments were performed in Chinese hamster ovary cells transfected with human NTCP, OATP1B1, OATP1B3, and OATP2B1. Conversely, excretory systems were tested with plasma membrane vesicles from Sf21 insect cells expressing human ABCB11, ABCC2, ABCC3, and ABCG2. In addition, plasma clearance and biliary excretion of CLF were examined in wild-type, Abcc2(-/-), and Abcc3(-/-) mice. Human Na(+)-dependent taurocholic-cotransporting polypeptide (NTCP) and ATP-binding cassette B11 (ABCB11) were incapable of transporting CLF. In contrast, high-affinity transport of CLF was observed for organic anion-transporting polypeptide 1B3 (OATP1B3), ABCC2, and ABCC3 with K(m) values of 4.6 +/- 2.7, 3.3 +/- 2.0, and 3.7 +/- 1.0 microM, respectively. In Abcc2(-/-) mice biliary excretion of CLF was strongly reduced compared with wild-type mice. This resulted in a much higher hepatic retention of CLF in Abcc2(-/-) versus wild-type mice: 64 versus 1% of the administered dose (2 h after administration). In mice intestinal uptake of CLF was negligible compared with that of taurocholate. Our conclusion is that human NTCP and ABCB11 are incapable of transporting CLF, whereas OATP1B3 and ABCC2/Abcc2 most likely mediate hepatic uptake and biliary excretion of CLF, respectively. CLF can be transported back into the blood by ABCC3. Enterohepatic circulation of CLF is minimal. This renders CLF suitable as an agent for assessing in vivo liver function.


Assuntos
Proteínas de Transporte/metabolismo , Ácidos Cólicos/farmacocinética , Fluoresceínas/farmacocinética , Corantes Fluorescentes/farmacocinética , Fígado/metabolismo , Animais , Bile/metabolismo , Transporte Biológico , Células CHO , Proteínas de Transporte/genética , Membrana Celular/efeitos dos fármacos , Membrana Celular/metabolismo , Cricetinae , Cricetulus , Humanos , Insetos/citologia , Insetos/metabolismo , Fígado/efeitos dos fármacos , Masculino , Camundongos , Camundongos Knockout , Proteína 2 Associada à Farmacorresistência Múltipla , Proteínas Associadas à Resistência a Múltiplos Medicamentos/genética , Proteínas Associadas à Resistência a Múltiplos Medicamentos/metabolismo , Transportadores de Ânions Orgânicos Dependentes de Sódio/metabolismo , Transportadores de Ânions Orgânicos Sódio-Independentes/genética , Transportadores de Ânions Orgânicos Sódio-Independentes/metabolismo , Membro 1B3 da Família de Transportadores de Ânion Orgânico Carreador de Soluto , Simportadores/metabolismo , Transfecção
10.
J Med Chem ; 52(24): 7958-61, 2009 Dec 24.
Artigo em Inglês | MEDLINE | ID: mdl-20014870

RESUMO

In the framework of the design and development of TGR5 agonists, we reported that the introduction of a C(23)(S)-methyl group in the side chain of bile acids such as chenodeoxycholic acid (CDCA) and 6-ethylchenodeoxycholic acid (6-ECDCA, INT-747) affords selectivity for TGR5. Herein we report further lead optimization efforts that have led to the discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a novel potent and selective TGR5 agonist with remarkable in vivo activity.


Assuntos
Ácidos Cólicos/farmacologia , Receptores Acoplados a Proteínas G/agonistas , Animais , Células CHO , Células COS , Chlorocebus aethiops , Ácidos Cólicos/química , Ácidos Cólicos/farmacocinética , Cricetinae , Cricetulus , Diabetes Mellitus/tratamento farmacológico , Humanos , Obesidade/tratamento farmacológico , Ratos , Receptores Acoplados a Proteínas G/metabolismo , Estereoisomerismo
11.
J Med Chem ; 52(21): 6889-96, 2009 Nov 12.
Artigo em Inglês | MEDLINE | ID: mdl-19827752

RESUMO

To develop an effective long-acting antidiabetic, the GLP-1 analogue of exendin-4 was modified with three different bile acids (BAs; cholic, deoxycholic, or lithocholic acid), at its two lysine residues. The biological, pharmaceutical, and physicochemical characteristics of these exendin-4 analogues were carefully investigated. Biological activity tests demonstrated that the monobile acid substitutions of exendin-4 showed well preserved receptor binding efficacy without noticeable insulinotropic or antidiabetic activity loss. However, physicochemical and pharmacokinetic studies revealed that the albumin-binding properties and in vivo elimination half-lives of BAM1-Ex4s (Lys(27)-BA-Ex4s) were significantly enhanced by increasing the hydrophobicities of the conjugated BAs. Furthermore, the protracted antidiabetic effects of the BAM1-Ex4s were also verified by the prolonged restoration of normoglycemia in type 2 diabetic mice. Accordingly, the present study suggests that the derivatization of exendin-4 with BAs offers a means of producing long-acting GLP-1 receptor agonists for type 2 diabetic therapy.


Assuntos
Ácidos Cólicos/síntese química , Hipoglicemiantes/síntese química , Peptídeos/síntese química , Receptores de Glucagon/agonistas , Peçonhas/síntese química , Animais , Linhagem Celular Tumoral , Ácidos Cólicos/farmacocinética , Ácidos Cólicos/farmacologia , Ácido Desoxicólico/análogos & derivados , Ácido Desoxicólico/síntese química , Ácido Desoxicólico/farmacocinética , Ácido Desoxicólico/farmacologia , Diabetes Mellitus Tipo 2/tratamento farmacológico , Exenatida , Receptor do Peptídeo Semelhante ao Glucagon 1 , Teste de Tolerância a Glucose , Interações Hidrofóbicas e Hidrofílicas , Hipoglicemiantes/farmacocinética , Hipoglicemiantes/farmacologia , Técnicas In Vitro , Ilhotas Pancreáticas/efeitos dos fármacos , Ilhotas Pancreáticas/metabolismo , Ácido Litocólico/análogos & derivados , Ácido Litocólico/síntese química , Ácido Litocólico/farmacocinética , Ácido Litocólico/farmacologia , Masculino , Camundongos , Peptídeos/farmacocinética , Peptídeos/farmacologia , Ligação Proteica , Ensaio Radioligante , Ratos , Ratos Sprague-Dawley , Albumina Sérica/metabolismo , Relação Estrutura-Atividade , Peçonhas/farmacocinética , Peçonhas/farmacologia
12.
Steroids ; 66(9): 673-81, 2001 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-11546555

RESUMO

Recently, a number of nuclear receptors have been identified as key regulators of cholesterol homeostasis. Two of these, liver X receptor alpha (LXRalpha) (NR1H3) [1] and ubiquitous receptor (UR) (NR1H2) [1], appear to be involved in cholesterol reverse transport and disposal. LXRalpha null gene mice fail to adapt metabolically to high-cholesterol diets. We have recently shown that some 6alpha-hydroxylated bile acid analogs are selective activators of LXRalpha. In this report, we show that these orally administered LXRalpha agonists have an overall hypolipidemic effect in hypercholesterolemic rats, mice and hamsters, which indicates that in these animal models, endogenous LXRalpha agonist is a limiting factor for induction of cholesterol disposal. Furthermore, in animals, these 6alpha-hydroxylated bile acid analogs exhibit a unique pharmacokinetic profile and do not increase the serum triglyceride level; therefore, they may represent a novel class of therapeutic agents for cholesterol management.


Assuntos
Colesterol/metabolismo , Hipolipemiantes/farmacologia , Receptores Citoplasmáticos e Nucleares/agonistas , Animais , Anticolesterolemiantes/farmacologia , Apolipoproteínas E/genética , Colesterol na Dieta/farmacologia , Ácidos Cólicos/administração & dosagem , Ácidos Cólicos/farmacocinética , Ácidos Cólicos/farmacologia , Cricetinae , Proteínas de Ligação a DNA , Modelos Animais de Doenças , Deleção de Genes , Humanos , Hidrocarbonetos Fluorados , Hipercolesterolemia/induzido quimicamente , Hipercolesterolemia/metabolismo , Hipolipemiantes/administração & dosagem , Hipolipemiantes/farmacocinética , Fígado/efeitos dos fármacos , Fígado/metabolismo , Fígado/patologia , Receptores X do Fígado , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Receptores Nucleares Órfãos , Ratos , Receptores Citoplasmáticos e Nucleares/metabolismo , Especificidade por Substrato , Sulfonamidas , Ativação Transcricional/efeitos dos fármacos , Triglicerídeos/metabolismo
13.
J Hepatol ; 34(2): 184-91, 2001 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-11281545

RESUMO

BACKGROUND/AIMS: S-adenosyl-L-methionine (SAMe) and tauroursodeoxycholate (TUDC) exert an additive ameliorating effect on taurolithocholate (TLC)-induced cholestasis. The aims were to investigate the protective effect of SAMe on 17beta-estradiol-glucuronide (17betaEG) cholestasis and to find out whether SAMe and TUDC may exert an additive, ameliorating effect. METHODS: Hepatocyte couplet function was assessed by canalicular vacuolar accumulation (cVA) of cholyllysylfluorescein (CLF). Cells were co-treated with 17betaEG and SAMe, TUDC, or both (protection study), or treated with 17betaEG and then with SAMe, TUDC or both (reversion study) before CLF uptake. Couplets were also co-treated with SAMe and dehydroepiandrosterone (DHEA), a competitive substrate for the sulfotransferase involved in 17betaEG detoxification. The effects of 17betaEG, SAMe and TUDC were also examined on intracellular distribution of F-actin. RESULTS: Both SAMe and TUDC significantly protected against, and reversed, 17betaEG-induced cholestasis, but their effects were not additive. DHEA abolished the protective effect of SAMe. 17BetaEG did not affect the uptake of CLF into hepatocytes at the concentrations used, and also, it did not affect the intracellular distribution of F-actin. CONCLUSIONS: 17BetaEG does not affect the uptake of CLF into hepatocytes. SAMe and TUDC protect and reverse 17betaEG-induced cholestasis, but without an additive effect. Protection by SAMe may involve facilitating the sulfation of 17betaEG.


Assuntos
Colestase/tratamento farmacológico , Colestase/prevenção & controle , S-Adenosilmetionina/farmacologia , Ácido Tauroquenodesoxicólico/farmacologia , Actinas/metabolismo , Animais , Transporte Biológico Ativo/efeitos dos fármacos , Colestase/induzido quimicamente , Colestase/metabolismo , Ácidos Cólicos/farmacocinética , Desidroepiandrosterona/farmacologia , Estradiol/análogos & derivados , Estradiol/toxicidade , Fluoresceínas/farmacocinética , Hepatócitos/efeitos dos fármacos , Hepatócitos/metabolismo , Técnicas In Vitro , Masculino , Ratos , Ratos Wistar , S-Adenosilmetionina/administração & dosagem , Ácido Tauroquenodesoxicólico/administração & dosagem
14.
J Hepatol ; 34(1): 4-10, 2001 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-11211906

RESUMO

BACKGROUND/AIMS: Lysyl fluorescein conjugated bile acid analogues (LFCBAA) closely parallel their natural counterparts. To assess LFCBAA as a tool for the visualization of bile acid transport within liver tissue. METHODS: Wistar rats were administered physiological concentrations of the primary bile acid analogue cholyllysyl fluoroscein (CLF) and of the secondary bile acid analogue lithocholyllysyl fluorescein (LLF) and serial liver biopsies were taken at fixed intervals. Both compounds were also injected retrogradely into the biliary tree. Frozen sections were examined by fluorescence microscopy. RESULTS: Both CLF and LLF were rapidly taken up from sinusoidal blood but differed significantly in their hepatic handling. CLF was rapidly transported into bile, whereas LLF transport was slower and produced significantly more bile duct fluorescence. LLF clearance showed a lobular gradient with last remaining bile acid being confined largely to zone 3. Both compounds were avidly taken up by cholangiocytes after injection intravenously or retrogradely into the biliary tree. CONCLUSIONS: Visualization of LFCBAA by fluorescence microscopy may yield further information regarding hepatobiliary bile acid localization during studies of physiological and pathological mechanisms involved in transport of bile acids. The presence of both compounds within cholangiocytes strongly suggests that they may undergo a degree of chole-hepatic recirculation.


Assuntos
Ácidos Cólicos/farmacocinética , Fluoresceínas/farmacocinética , Corantes Fluorescentes/farmacocinética , Ácido Litocólico/análogos & derivados , Ácido Litocólico/farmacocinética , Fígado/metabolismo , Lisina/análogos & derivados , Lisina/farmacocinética , Animais , Transporte Biológico , Biópsia , Masculino , Microscopia de Fluorescência , Ratos , Ratos Wistar
15.
Hepatology ; 32(6): 1342-56, 2000 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-11093742

RESUMO

Hormonal control of the restoration of hepatocanalicular polarity in short-term cultured hepatocyte couplets was analyzed. One hour following isolation, couplets were unable to accumulate the fluorescent bile acid analogue, cholyl-lysyl-fluorescein (CLF), and showed a nonpolarized distribution of F-actin and mrp2 over the cell body. A progressive, time-dependent restoration of couplet-polarized function and morphology was reached after 4 hours of culture. Both dibutyryl cyclic adenosine monophosphate (DBcAMP) and the Ca(2+)-elevating compound, thapsigargin, accelerated restoration of normal couplet morphology and function. The DBcAMP-mediated stimulus was inhibited by the Ca(2+) chelator, 1, 2-bis-(o-aminophenoxy)-ethene-N,N,N',N'-tetra-acetate tetra-(acetomethyl)ester (BAPTA/AM), but not by the protein kinase A (PKA) inhibitors, KT5720 or H89, suggesting that Ca(2+) elevation rather than PKA activation is involved. N-(6-aminohexyl-5-chloro-1-napththalenesulfonamide (W-7), a calmodulin inhibitor, and the protein kinase C (PKC) activator, phorbol dibutyrate, inhibited both the basal and the DBcAMP-stimulated recovery of functional polarity, whereas staurosporine and Gö 6976, 2 PKC inhibitors, accelerated the basal recovery of polarized function. Disruption of the microtubule cytoskeleton by colchicine induced only minor changes under basal, but not under DBcAMP-stimulated, conditions. The Golgi complex disruptor, brefeldin A, significantly delayed, and the microfilament-disrupting agent, cytochalasin D, fully blocked, both processes. However, DBcAMP stimulated trafficking of vesicles containing CLF to the pericanalicular region under the last condition. Our results indicate that restoration of couplet polarity following isolation occurs via a Ca(2+)-calmodulin-mediated mechanism, which depends on microfilament, but not on microtubule integrity. A second pathway is activated by DBcAMP activation via Ca(2+)-calmodulin formation, whose requirements with respect to cytoskeletal components are opposite. PKC has a negative regulatory role in both pathways.


Assuntos
Canalículos Biliares/metabolismo , Proteínas de Transporte/metabolismo , Citoesqueleto/fisiologia , Hepatócitos/metabolismo , Transdução de Sinais/fisiologia , Actinas/fisiologia , Animais , Proteínas de Transporte de Ânions , Canalículos Biliares/fisiologia , Membrana Celular/metabolismo , Células Cultivadas , Senescência Celular/fisiologia , Ácidos Cólicos/farmacocinética , Citoplasma/metabolismo , Fluoresceínas/farmacocinética , Corantes Fluorescentes/farmacocinética , Hormônios/fisiologia , Masculino , Ratos , Ratos Wistar , Vacúolos/fisiologia
16.
17.
Liver ; 20(4): 330-4, 2000 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-10959812

RESUMO

BACKGROUND: Cholyl-lysyl-fluorescein (CLF) is a fluorescein-labelled bile acid whose biological behaviour closely resembles that of naturally occurring cholyl glycine. AIM: The aim of this study was to analyze the CLF plasma elimination in patients with liver cirrhosis. METHODS: A dose of CLF at 0.02 mg/kg b.w. was administered i.v. in 26 patients with liver cirrhosis and 9 healthy volunteers. Blood samples were collected before injection and then at 10 min intervals over 60 min. Plasma fluorescence was measured by a luminescence spectrometer and residual fluorescence over the time of the study was compared in each group. Routine liver function tests (rLFTs) were performed before each injection. RESULTS: Plasma elimination of CLF was significantly impaired in patients with cirrhosis compared to healthy subjects with p values <0.0001 at each analyzed time point. CLF test showed 100% sensitivity for liver cirrhosis when residual fluorescence was measured 30, 40, 50 and 60 min after injection. Routine LFTs showed 85% sensitivity for bilirubin, 84% for total bile acids, 69% for aspartate aminotransferase 62% for albumin and 50% for alkaline phosphatase. CLF elimination measured 60 min after injection correlated with Child-Pugh score (r=0.3945; p<0.05) and albumin (rs=0.6451; p<0.001). No adverse reaction or side effects of CLF were observed. CONCLUSIONS: CLF test clearly distinguished between the two analyzed groups and was more sensitive than routine liver function tests. The test appears safe, simple to perform and analyze and after validation in larger cohorts of patients may have the potential to become a useful dynamic test of liver function.


Assuntos
Ácidos Cólicos/farmacocinética , Fluoresceínas/farmacocinética , Corantes Fluorescentes/farmacocinética , Cirrose Hepática/metabolismo , Adulto , Ácidos Cólicos/administração & dosagem , Feminino , Fluoresceínas/administração & dosagem , Corantes Fluorescentes/administração & dosagem , Humanos , Injeções Intravenosas , Fígado/metabolismo , Fígado/patologia , Cirrose Hepática/diagnóstico , Testes de Função Hepática , Masculino , Pessoa de Meia-Idade , Projetos Piloto , Valores de Referência , Sensibilidade e Especificidade
18.
Dig Dis Sci ; 44(12): 2478-83, 1999 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-10630500

RESUMO

As immunosuppressive agents, corticosteroids may be considered an appropriate treatment for primary biliary cirrhosis, even if bone loss and other side effects may occur. We studied biliary lipid metabolism in 10 nonicteric patients, with histologically proven primary biliary cirrhosis (stage I-IV). We administered methylprednisolone (24 mg daily) for 30 days to ascertain its effects on biliary lipid metabolism, which are largely still unknown. All patients underwent a 30-day drug-washout period before entering the trial. The following parameters were studied before and after methylprednisolone treatment: serum biochemistry; cholic acid pool size, kinetics and synthesis; biliary lipid secretion; biliary bile acid pattern; biliary lipid molar percentage; and cholesterol saturation index. Methylprednisolone induced a statistically significant (Wilcoxon rank test) increase in cholic acid turnover (from 0.26+/-0.04 to 0.50+/-0.05 K/day, P = 0.005) and synthesis (from 0.42+/-0.12 to 0.78+/-0.11 mmol/day, P = 0.04), and in bile deoxycholic acid molar percentage (from 19.4+/-2.7 to 30.6+/-4.4% molar, P = 0.01). On the other hand, a significant decrease in biliary cholesterol molar percentage (from 7.9+/-0.7 to 6.4+/-0.5% molar, P = 0.005), cholesterol saturation index (from 1.11+/-0.11 to 0.95+/-0.07, P = 0.05), and biliary cholesterol secretion (from 64.7+/-5.4 to 53.0+/-4.5 micromol/hr, P = 0.005) was observed. These findings show that short-term administration of methylprednisolone in patients with primary biliary cirrhosis does not induce expansion of the cholic acid pool but increases cholic acid synthesis and turnover, as well as intestinal production of deoxycholic acid. If long-term treatment is considered, the beneficial immunosuppressive effects of corticosteroids have to be weighed against the hepatotoxic properties of deoxycholic acid.


Assuntos
Bile/química , Ácidos Cólicos/metabolismo , Ácido Desoxicólico/análise , Glucocorticoides/administração & dosagem , Imunossupressores/administração & dosagem , Cirrose Hepática Biliar/metabolismo , Metilprednisolona/administração & dosagem , Adulto , Idoso , Colesterol/análise , Ácidos Cólicos/farmacocinética , Feminino , Humanos , Cirrose Hepática Biliar/tratamento farmacológico , Pessoa de Meia-Idade
19.
J Chromatogr B Biomed Sci Appl ; 700(1-2): 59-66, 1997 Oct 24.
Artigo em Inglês | MEDLINE | ID: mdl-9390714

RESUMO

A method based on coupling of the techniques of radioscanning a TLC plate and densitometry has been developed for the determination of pool sizes and fractional turnover rate of bile acids in man after intraduodenal administration of 14C-labelled acid. The validity of the method has been checked by comparison of the results obtained with those of an enzymatic spectrophotometric analysis, and a measurement of the radioactivity by liquid scintillation counting, after elution of the separated bile acid from a TLC plate. Advantages of the proposed method over the previous one include a reduced number of manipulations, the possibility of automation, a better reproducibility, and the possibility of elaborating the radiometric data obtained for the primary bile acid for better characterising its metabolism inside the enterohepatic circulation.


Assuntos
Ácidos Cólicos/farmacocinética , Ácido Desoxicólico/farmacocinética , Radioisótopos de Carbono , Ácido Cólico , Ácidos Cólicos/metabolismo , Cromatografia em Camada Fina , Densitometria , Ácido Desoxicólico/metabolismo , Humanos , Técnica de Diluição de Radioisótopos , Reprodutibilidade dos Testes
20.
Yale J Biol Med ; 70(4): 447-57, 1997.
Artigo em Inglês | MEDLINE | ID: mdl-9626765

RESUMO

There have been attempts to couple bile acids to fluorescein to permit their visualization during studies of physiology and pathophysiology. Although conjugation has been achieved by many, the product differed in many respects from the parent bile acid congener. We describe lysylfluorescein conjugated bile acid analogues (LFCBAA) synthesized in our laboratory as model divalent "unipolar" molecules. We have determined LFCBAA properties including their water:octanol partition coefficient, HPLC retention time and critical micellar concentration and compared them with their parent bile acid congeners. Cholyl lysylfluorescein (CLF) and lithocholyl lysylfluoroscein (LLF) have properties similar to cholylglycine (CG) and glycolithocholate (GLC), respectively. In human and rat hepatocytes uptake of CLF follows Michaelis-Menten kinetics with K(m) and Vmax similar to CG. Biliary excretion rates of CLF and LLF closely resemble those of CG and GLC in both normal and mutant TR- rats which lack the multiorganic anion transporter (MOAT), strongly supporting the notion that CLF and LLF are substrates for the canalicular bile salt transporter (cBST). The close similarity of hepatocyte uptake and biliary secretion of these LFCBAA and their parent bile acid congeners makes them potentially useful probes for the intracellular visualization of bile salt movement and deposition in various models of bile formation and secretion.


Assuntos
Ácidos e Sais Biliares/química , Ácidos Cólicos/química , Fluoresceínas/química , Corantes Fluorescentes/química , Animais , Bile/metabolismo , Ácidos e Sais Biliares/síntese química , Ácidos e Sais Biliares/metabolismo , Sistema Biliar/metabolismo , Transporte Biológico Ativo , Ácidos Cólicos/síntese química , Ácidos Cólicos/farmacocinética , Fluoresceínas/síntese química , Fluoresceínas/farmacocinética , Corantes Fluorescentes/síntese química , Corantes Fluorescentes/farmacocinética , Humanos , Técnicas In Vitro , Cinética , Fígado/metabolismo , Ratos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...